Next Article in Journal
Next Generation Sequencing Discoveries of the Nitrate-Responsive Oral Microbiome and Its Effect on Vascular Responses
Next Article in Special Issue
Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?
Previous Article in Journal
Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis
Previous Article in Special Issue
The Future of Lipid-Lowering Therapy
Open AccessReview

Inflammation as a Therapeutic Target in Atherosclerosis

1
Vascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, South Australia 5000, Australia
2
Adelaide Medical School, University of Adelaide, Adelaide, South Australia 5000, Australia
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(8), 1109; https://doi.org/10.3390/jcm8081109
Received: 5 June 2019 / Revised: 18 July 2019 / Accepted: 20 July 2019 / Published: 26 July 2019
(This article belongs to the Special Issue Developing Novel Therapies to Prevent Atherosclerosis)
Atherosclerotic coronary artery disease (CAD) results from build-up of cholesterol-rich plaques in the walls of the coronary arteries and is a leading cause of death. Inflammation is central to atherosclerosis. Uncontrolled inflammation makes coronary plaques “unstable” and vulnerable to rupture or erosion, leading to thrombosis and myocardial infarction (MI). As multiple inflamed plaques often co-exist in the coronary system, patients are at risk of repeated atherothrombotic cardiovascular events after MI, with rates of 10–12% at one year and 18–20% at three years. This is largely because current therapies for CAD, such as lipid-lowering statins, do not adequately control plaque inflammation. New anti-atherosclerotic agents are therefore needed, especially those that better target inflammation. The recent positive results for the anti-interleukin-1-beta (IL-1β) monoclonal antibody, Canakinumab, in the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) clinical trial has provided a major stimulant to the field. It highlights that not only is inflammation important from a pathogenic and risk prediction perspective in CAD, but that reducing inflammation can be beneficial. The challenge is now to find the best strategies to achieve this in real-world practice. This review outlines the role that inflammation plays in atherosclerosis and provides an update on anti-inflammatory therapies currently being investigated to target atherosclerosis. View Full-Text
Keywords: inflammation; atherosclerosis; C-reactive protein; canakinumab; methotrexate; colchicine; interleukin inflammation; atherosclerosis; C-reactive protein; canakinumab; methotrexate; colchicine; interleukin
Show Figures

Figure 1

MDPI and ACS Style

Nguyen, M.T.; Fernando, S.; Schwarz, N.; Tan, J.T.; Bursill, C.A.; Psaltis, P.J. Inflammation as a Therapeutic Target in Atherosclerosis. J. Clin. Med. 2019, 8, 1109.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop